Sharon Brangman, MD, is the chief of geriatrics at Upstate Medical University.
Newly approved Alzheimer's drug Aduhelm is not for everyone, and questions remain, says chief of geriatrics
A new drug for people with Alzheimer’s disease was approved by the FDA recently, but the approval has been controversial. The drug is aducanumab, marketed under the name Aduhelm. Sharon Brangman, MD -- chief of geriatrics at Upstate and a former president of the American Geriatrics Society -- explains what's important to know about the medication and why it's not intended for everyone with dementia.